FDA Approves Upadacitinib (Rinvoq) for Sixth Indication

Upadacitinib's approval for nonradiographic axial spondyloarthritis marks the sixth indication in the US for the Janus kinase inhibitor.
FDA Approvals

source https://www.medscape.com/viewarticle/982902?src=rss